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Abstract
Background:  New antimalarial regimens, including artemisinin-based combination therapies
(ACTs), have been adopted widely as first-line treatment for uncomplicated malaria. Although
these drugs appear to be safe and well-tolerated, experience with their use in Africa is limited and
continued assessment of safety is a priority. However, no standardized guidelines for evaluating
drug safety and tolerability in malaria studies exist. A system for monitoring adverse events in
antimalarial trials conducted in Uganda was developed. Here the reporting system is described, and
difficulties faced in analysing and interpreting the safety results are illustrated, using data from the
trials.
Case description: Between 2002 and 2007, eleven randomized, controlled clinical trials were
conducted to compare the efficacy, safety, and tolerability of different antimalarial regimens for
treatment of uncomplicated malaria in Uganda. The approach to adverse event monitoring was
similar in all studies. A total of 5,614 treatments were evaluated in 4,876 patients. Differences in
baseline characteristics and patterns of adverse event reporting were noted between the sites,
which limited the ability to pool and analyse data. Clinical failure following antimalarial treatment
confounded associations between treatment and adverse events that were also common symptoms
of malaria, particularly in areas of lower transmission intensity.
Discussion and evaluation: Despite prospectively evaluating for adverse events, limitations in
the monitoring system were identified. New standardized guidelines for monitoring safety and
tolerability in antimalarial trials are needed, which should address how to detect events of greatest
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importance, including serious events, those with a causal relationship to the treatment, those which
impact on adherence, and events not previously reported.
Conclusion:  Although the World Health Organization has supported the development of
pharmacovigilance systems in African countries deploying ACTs, additional guidance on adverse
events monitoring in antimalarial clinical trials is needed, similar to the standardized
recommendations available for assessment of drug efficacy.
Background
Since 2004, antimalarial treatment in sub-Saharan Africa
has changed dramatically. As a result of widespread resist-
ance to chloroquine and sulphadoxine-pyrimethamine,
most sub-Saharan African countries have recently revised
their antimalarial drug policies, selecting new artemisi-
nin-based combination therapies (ACTs) as first-line
treatment for uncomplicated malaria [1]. Although these
drugs appear to be safe and well-tolerated, experience
with their use in Africa is limited and continued assess-
ment of ACT safety is a priority [2]. Artemether-lumefan-
trine and artesunate-amodiaquine were initially chosen as
first-line regimens in most African countries [3]. However,
several additional regimens, including dihydroartemisi-
nin-piperaquine, have recently been introduced and are
being considered for widespread use [4-6]. With increas-
ing availability of highly effective ACTs, selection of the
optimal regimen will be driven by factors other than effi-
cacy, including safety and tolerability, ease of administra-
tion, and cost. Comparative evaluations of the safety and
tolerability of new regimens will become increasingly
important for informing treatment decisions and policy.
Guidelines for assessing the efficacy of antimalarial treat-
ments have been provided by the World Health Organiza-
tion (WHO) [7-9]. However, although the importance of
pharmacovigilance for antimalarial treatment has been
increasingly recognized, there are no standardized recom-
mendations for evaluating drug safety and tolerability in
antimalarial trials [2,10,11]. Guidelines for laboratory
testing are also lacking. In addition, few antimalarial stud-
ies publish detailed methods on the collection of safety
data [5,12-15]. The lack of a standardized approach to
adverse event monitoring limits the ability to compare
data collected in different studies.
To evaluate the safety and tolerability of newer combina-
tion antimalarial therapies, a system for monitoring
adverse events in clinical trials conducted in Uganda since
2002 was developed. This system has been used in studies
evaluating treatment of single episodes of uncomplicated
malaria, and in a longitudinal cohort study evaluating
repeated antimalarial treatments. Here the reporting sys-
tem is described, and difficulties faced in analysing and
interpreting the safety data are discussed. The challenges
of adverse event monitoring and key areas that need to be
addressed in developing guidelines for assessing the safety
and tolerability of antimalarial drugs are highlighted.
Case description
Study design
From 2002 to 2007, eleven randomized, controlled clini-
cal trials were conducted to compare the efficacy, safety,
and tolerability of different combination antimalarial reg-
imens for treatment of uncomplicated malaria in Uganda
(Table 1). Ten of the trials evaluated treatment of single
episodes of malaria using a similar study design and a
common protocol [5,15-18]. One trial was a longitudinal
study of a cohort of children comparing three different
combination regimens for treatment of repeated episodes
of uncomplicated malaria [19,20,27].
Ethical approval for the studies was obtained from the
Uganda National Council for Science and Technology (all
studies); the University of California, San Francisco Com-
mittee on Human Research (all studies); the Makerere
University Research and Ethics Committee (Kampala
studies, and UMSP 4); and the University of California,
Berkeley (UMSP 1, 2, and 3).
Study sites
Kampala is an urban center where malaria is meso-
endemic (25% palpable spleen rate, 25% parasitaemia
rate, Uganda Ministry of Health, unpublished data,
1994). The UMSP study sites, selected for geographic
diversity, included: Kanungu (rural, low transmission),
Kyenjojo (rural, medium transmission), Mubende (rural,
medium transmission), Arua (rural, high transmission),
Apac (rural, very high transmission), Tororo (rural, very
high transmission), and Jinja (peri-urban, medium trans-
mission) (Figure 1). The level of malaria transmission
intensity at the UMSP sites has been further characterized
by estimates of entomological inoculation rates (Figure 1)
[21].
Baseline clinical and laboratory evaluations
The study procedures for all eleven clinical trials have
been previously reported [5,15-18,20]. On the day of
malaria diagnosis (day 0), a standard clinical evaluation
was performed, including history and physical examina-
tion. Guidelines for conducting the physical examination
were provided (Additional File 1). In the initial studiesMalaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
Page 3 of 10
(page number not for citation purposes)
(Kampala 1 and UMSP 1 and 2), a brief neurologic assess-
ment, consisting of tests for coordination (heel-toe
ataxia), fine finger dexterity (ability to pick up a small
object), hearing, nystagmus, and balance (Romberg test),
was conducted in appropriate aged children. In the later
studies (UMSP 3 and 4, and Kampala 2), only fine finger
dexterity and hearing were routinely evaluated.
Baseline laboratory evaluations in the Kampala studies
included thick and thin blood smears, complete blood
count, alanine aminotransferase (ALT), and creatinine
(Kampala 1 only). In the UMSP studies, blood was
obtained by finger-prick for thick and thin blood smears,
and haemoglobin measurement.
Antimalarial treatment allocation and blinding
Participants were randomly assigned study treatment in
all trials, although procedures varied slightly between
studies. Details on randomization, treatment allocation
and administration, and blinding are included in the ini-
tial study reports [5,15-18,20]. For all studies, the only
study personnel aware of the treatment assignments were
the nurses responsible for allocating and administering
treatment. Study participants were not informed of their
assigned treatment regimen.
Follow-up clinical and laboratory evaluations
The standardized history and physical examination was
repeated at all scheduled and unscheduled follow-up vis-
its. Follow-up laboratory assessments in the Kampala
studies included thick blood smears, complete blood
count and ALT (on days 7 and 28 in Kampala 1, and day
14 in Kampala 2), and creatinine (on days 7 and 28 in
Kampala 1). In the UMSP studies, repeat assessments
included thick blood smears, and haemoglobin on the
final day of follow-up or the day of treatment failure.
Adverse event monitoring
The approach to adverse event monitoring was similar in
all studies. An adverse event was defined as any untoward
Table 1: Summary of antimalarial clinical trials conducted in Uganda 2002 – 2007
Trial Kampala 1 UMSP 1 UMSP 2 UMSP 3 UMSP 4 Kampala 2
Study site(s) Kampala Kyenjojo, 
Mubende, Kanungu
Jinja, Arua, Tororo, 
Apac
Tororo Apac Kampala
Years conducted August 2002 – July 
2003
December 2002 – 
June 2003
November 2002 – 
May 2004
December 2004 – 
July 2005
May – July 2006 November 2004 – 
May 2007
Regimens 
evaluated*
CQ+SP CQ+SP CQ+SP AS+AQ AL AQ+SP
AQ+SP AQ+SP AQ+SP AL DP AS+AQ
AS+AQ AS+AQ AL
Duration of 
follow-up
28 days 28 days 28 days 42 days 42 days 42 days
Age range of 
participants
0.5 – 10 years ≥ 6 months ≥ 6 months 1 – 10 years 0.5 – 10 years 1 – 10 years
Total study 
treatments
400 1105 2160 408 421 1120 †
Efficacy outcome 
assigned
384 (96%) 1057 (96%) 2081 (96%) 403 (99%) 417 (99%) 1108 (99%)
Total SAEs 16 41 20 2 6 18
Convulsions 4 15 4 1 3 9
Altered mental 
status
1020 0 0
Anemia 5 6 3 0 0 0
Vomiting 2 13 1 0 0 1
Weakness 0 3 1 0 0 2
Respiratory 
illness
1141 0 2
Other 3 3 5 0 3 4
* CQ+SP: chloroquine + sulphadoxine-pyrimethamine; AQ+SP: amodiaquine + sulphadoxine-pyrimethamine; AS+AQ: artesunate + amodiaquine; 
AL: artemether-lumefantrine; DP: dihydroartemisinin-piperaquine
† Of 602 children enrolled into the Kampala 2 cohort study, 382 were diagnosed with at least one episode of uncomplicated malaria and were 
treated with a total of 1120 study treatments.Malaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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medical occurrence, irrespective of its suspected relation-
ship to the study medications as per International Confer-
ence of Harmonization (ICH) guidelines for Good
Clinical Practice (GCP) [22]. A serious adverse event was
defined as any adverse experience that was life threaten-
ing, or resulted in death, hospitalization, persistent or sig-
nificant disability or incapacity, or required a specific
medical or surgical intervention to prevent serious out-
come.
Study sites in Uganda and malaria endemicity Figure 1
Study sites in Uganda and malaria endemicity.Malaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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At each participant encounter a standardized system was
used to assess symptoms, physical exam findings, and lab-
oratory test results based on grading of severity (Addi-
tional File 2). The severity grading scales were adapted
from guidelines provided by the World Health Organiza-
tion (Toxicity Grading Scale for Determining the Severity
of Adverse Events) and the National Institutes of Health,
Division of Microbiology and Infectious Diseases (Pediat-
ric Toxicity Tables, May 2001). Active assessment for spe-
cific symptoms was conducted in all participants,
including weakness, anorexia, vomiting, diarrhoea,
cough, pruritus, and coryza. Headache, abdominal pain,
and nausea were also assessed in children over three years
of age. Any additional symptoms reported by the partici-
pant or findings noted in physical exam were assessed and
graded accordingly.
Adverse events were identified by evaluating for any new
or worsening symptoms, physical exam findings, or labo-
ratory abnormalities. An adverse event was identified
based on an increase in the severity score as compared to
the previous evaluation. Participants with abnormalities
present at baseline (on day 0) would not be classified as
experiencing an adverse event unless the symptom wors-
ened from baseline, or resolved and then recurred. For all
adverse events of moderate or greater severity, additional
information was captured, including the suspected rela-
tionship of the event to the study treatment. In the ten
studies evaluating treatment of single episodes of malaria,
relationship was classified as not related, or unlikely, pos-
sibly, probably, or definitely related to study medications.
In the Kampala longitudinal study, the classification was
similar, but the 'unlikely' category was excluded. Data
were double-entered individually for each study into Epi-
Info version 6.04 or Access (Microsoft Corporation, Red-
mond, Washington) and analysed using Stata version 8.0
(Stata Corporation, College Station, TX, USA). Categorical
variables were compared using the chi-square test or
Fisher's exact test. Continuous variables were compared
using two-sample t-tests.
Study population and summary of adverse events
A total of 5,614 study treatments were evaluated in 4,876
patients enrolled in the eleven clinical trials (Table 1).
Serious adverse events were uncommon, and no impor-
tant neurological events or severe dermatologic reactions
were detected. Convulsions were the most commonly
reported serious adverse event, followed by vomiting
(Table 1). Of the 103 serious adverse events reported,
none were classified as definitely related to treatment;
most were considered to be unrelated (14 events),
unlikely related (36 events), or possibly related (48
events) to the study medications (data not shown). Of the
five serious events that were classified as probably related,
all were episodes of vomiting. Two deaths occurred in the
studies. One patient died of suspected severe malnutri-
tion, and one patient died of congestive heart failure due
to a presumed congenital heart defect (both patients had
received AQ+SP).
Two important laboratory abnormalities were detected in
the Kampala studies (Table 2). In the first Kampala study,
one patient successfully treated with AQ+SP developed
life-threatening thrombocytopaenia, neutropaenia, and
anaemia, which were considered possibly related to the
study medications [16]. Severe thrombocytopaenia
(33,000/ul) was present at enrolment, persisted at day 7
(32,000/ul), and worsened by day 28 (20,000/ul). Severe
neutropaenia and anaemia developed, and the child
became transfusion-dependent. A bone marrow biopsy
revealed hypoplastic marrow of undetermined cause with
all cell lines present. The child survived, but the aetiology
of the pancytopaenia was not identified. In the longitudi-
nal Kampala study, one child developed repeated epi-
sodes of neutropaenia (four mild, one moderate, one
severe) after AS+AQ treatment and was subsequently
withdrawn from the study.
Variability between study sites
The baseline characteristics of the study populations dif-
fered between the study sites. To demonstrate this varia-
bility, data are presented for the five trials comparing
CQ+SP, AQ+SP, and AS+AQ, which were conducted in
Kampala, Jinja, Arua, Tororo, and Apac (Table 2). The
other studies are not included as they did not compare the
same regimens, and/or used slightly different study proto-
cols. Significant differences in participant age, mean hae-
moglobin, prior treatment, administration of
concomitant medications, and risk of clinical treatment
failure were observed (p < 0.001 for all comparisons). In
addition, differences in the pattern of adverse event
reporting were also noted. The mean number of adverse
events per participant ranged from 2.5 in Jinja to 5.8 in
Tororo (p < 0.001), and most events were mild or moder-
ate in severity. However, the severity grading appeared to
vary between the sites with the proportion of events
graded as mild ranging from 47% in Tororo to 76% in
Arua (p < 0.001). The majority of events were classified as
unlikely or possibly related to the study treatment at all
sites, but classification of relationship also varied.
Clinical treatment failure and analysis of adverse events
In the studies evaluating single episodes of malaria, all
symptoms of recurrent malaria, whether due to recrudes-
cence or new infection, were captured as adverse events. In
the analysis, clinical treatment failure, due to recrudes-
cence and new infections, was a confounder for some, but
not all, adverse events. Affected events included fever,
weakness, anorexia, vomiting and elevated temperature,
all common symptoms of malaria. Clinical treatment fail-Malaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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ure did not appear to confound associations between
study treatment and events which were less likely to be
symptoms of malaria, including abdominal pain, diar-
rhoea, cough, pruritus, and coryza.
Figure 2 illustrates this issue using the data collected for
weakness in the five studies comparing CQ+SP, AQ+SP,
and AS+AQ. Comparing the proportion of all participants
in the treatment groups who developed an adverse event
of weakness across the sites, significant differences were
found in Kampala (p = 0.032), and in Jinja (p = 0.001),
with CQ+SP associated with the highest risk of weakness.
However, when the analysis was restricted by excluding
clinical treatment failures, these differences were not sus-
tained. In Kampala, the proportion of participants experi-
encing weakness fell from 42% to 22% in the CQ+SP
group, and no difference was detected between the three
treatment groups (p = 0.998). Similar results were seen in
Jinja. Comparisons of risk of weakness between the treat-
ment groups in the other sites were not significant for
either analysis population. However, when clinical treat-
ment failures were excluded the risk of weakness
decreased in all groups at all sites.
Challenges with data analysis
Analysis of the safety data presented several challenges.
The adverse event data collected at the different sites was
to be pooled in order to increase the power for detecting
differences between the study treatments. However, the
significant differences in baseline characteristics, trans-
mission intensity, local treatment practices, and pattern of
adverse event reporting at the different sites, limited the
ability to effectively combine the data. The confounding
effect of clinical treatment failure on the association
between study treatments and adverse events was another
challenge, as was the large number of adverse event out-
comes and adverse events reported. To address this, sev-
eral analytical approaches were considered. The analysis
was restricted by excluding treatment failures and by
excluding mild events. However, excluding treatment fail-
ures limited the available data, particularly in areas of
high transmission. Excluding mild events also limited the
data and the ability to assess for less severe events which
Table 2: Summary of studies comparing CQ+SP, AQ+SP, and AS+AQ demonstrating variability between study sites
Trial Kampala 1 UMSP 2
Study site Kampala Jinja Arua Tororo Apac
Total participants enrolled 400 543 534 541 542
Median age years (IQR) 4.2 (+/- 4.6) 3.6 (+/- 5.5) 1.5 (+/- 1.4) 1.3 (+/- 1.5) 1.8 (+/- 1.9)
Age < 5 years 221 (55%) 332 (61%) 497 (93%) 500 (92%) 489 (90%)
Mean Hb Day 0 (SD) 10.2 (1.9) 10.6 (2.3) 9.3 (1.7) 9.0 (1.9) 9.3 (1.9)
Medications taken in past 2 weeks 167 (41%) 322 (59%) 83 (16%) 212 (39%) 196 (36%)
≥ 3 Additional medications prescribed N/A 100/543 (18%) 150/534 (28%) 385/541 (71%) 50/542 (9%)
Risk of clinical treatment failure
CQ+SP 59/126 (47%) 128/160 (46%) 50/178 (72%) 116/162 (72%) 52/180 (29%)
AQ+SP 18/130 (14%) 24/173 (14%) 73/174 (42%) 73/172 (42%) 28/178 (16%)
AQ+AS 16/130 (12%) 24/181 (13%) 62/171 (36%) 93/181 (51%) 46/172 (27%)
Mean AEs (SD) per participant 4.6 (3.3) 2.5 (2.2) 4.3 (2.2) 5.8 (2.5) 3.6 (2.2)
Participants reporting AEs (%) 371/396 (94) 438/540 (81) 521/534 (98) 534/541 (99) 522/541 (96)
CQ+SP 127/131 (97) 149/168 (89) 174/180 (97) 166/166 (100) 181/185 (98)
AQ+SP 120/132 (91) 143/185 (77) 176/180 (98) 178/181 (98) 175/182 (96)
AQ+AS 124/133 (93) 146/187 (78) 171/174 (98) 190/194 (98) 166/174 (95)
Total AEs by severity (%) N = 1828 N = 1348 N = 2287 N = 3117 N = 1955
Mild 878 (48) 756 (56) 1736 (76) 1462 (47) 1322 (68)
Moderate 898 (49) 557 (41) 529 (23) 1622 (52) 613 (31)
Severe 48 (3) 30 (2) 21 (1) 31 (1) 20 (1)
Life-threatening 4 (0.2) 5 (0.4) 1 (0.4) 2 (0.1) 0
Total AEs by relationship* (%) N = 1828 N = 554 N = 551 N = 1655 N = 631
Unlikely 1129 (62) 292 (53) 424 (77) 1159 (70) 384 (61)
Possible 480 (26) 248 (45) 127 (23) 464 (28) 238 (38)
Probable 199 (11) 14 (3) 0 32 (2) 9 (1)
D e f i n i t e 0 000 0
* At UMSP sites (Jinja, Arua, Tororo, Apac), data on relationship was collected only for adverse events of moderate or greater severityMalaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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might have an impact on adherence. A multivariate logis-
tic regression model was also attempted to control for
treatment failure and other potential predictors of adverse
events. However, the number of adverse event outcomes
and multiple comparisons still presented a challenge to
the presentation and interpretation of the data.
Discussion and evaluation
Identifying and defining adverse events
Systematic assessment for adverse events, applying the
broad ICH GCP definitions, was conducted in eleven anti-
malarial clinical trials. The substantial number of adverse
event reports collected made evaluating for clinically
important events, determining causality, and detecting
relevant differences between antimalarial treatments,
challenging. Although defining an adverse event as 'any
untoward medical occurrence' ensures maximum sensitiv-
ity in capturing events, such a broad definition may not be
ideal for antimalarial clinical trials. Assessment of adverse
events in malaria studies is complicated by the overlap
between symptoms of malaria and common drug side
effects. The frequent occurrence of non-malarial illnesses,
including viral infections and respiratory illnesses is also
problematic, particularly in children.
Clinical monitoring
Active assessment for specific symptoms and signs was
conducted at all scheduled and unscheduled follow-up
visits, rather than just relying on patient reports. This
likely increased the number of adverse events detected,
but allowed differences in tolerability to be captured,
which may have been missed without systematic screen-
ing. Given the potential for neurotoxicity associated with
artemisinins [23], simple neurological examinations were
systematically performed in the studies. However, no
important neurologic abnormalities were detected, raising
the question of whether neurologic examinations should
be routinely conducted in antimalarial clinical trials.
Although routine screening is likely to be low yield, tar-
geted assessments of neurological function, including
audiometric testing for hearing, in populations at higher
risk of adverse events such as young children and patients
receiving repeated treatments may be more useful. Guide-
lines to standardize methods for assessing symptoms and
conducting physical examinations are needed. Even sub-
tle differences in the approach to defining symptoms,
measuring temperature, and conducting physical exami-
nations may affect the ability to pool data collected at dif-
ferent sites.
Laboratory monitoring
Laboratory testing is an important component of safety
monitoring. Recommendations on laboratory testing,
specifically addressing the methodology and timing of
follow-up evaluations, and which tests to conduct, would
also be useful. In the Kampala studies, follow-up labora-
tory tests were conducted at different intervals due to dif-
ferences in study design and requests of the study
sponsors, limiting the ability to combine the data. Ideally,
laboratory testing could be guided by the known pharma-
cokinetic and pharmacodynamic properties of the drugs,
and standardized intervals for testing could be estab-
lished. The choice of tests for routine screening should be
guided by the drugs being assessed and any specific safety
concerns. Once initial problems are detected with routine
testing, additional diagnostic testing is often required.
Even if sites have the capacity to perform routine tests, the
capacity for more sophisticated assessments is often lack-
ing. Establishing centralized laboratories where samples
could be sent for more advanced testing would help sup-
port laboratory testing and safety monitoring.
Clinical treatment failure and analysis of adverse events Figure 2
Clinical treatment failure and analysis of adverse 
events. The proportion of participants experiencing an 
adverse event of weakness in the five studies comparing chlo-
roquine + sulphadoxine-pyrimethamine (CQ+SP), amodi-
aquine + sulphadoxine-pyrimethamine (AQ+SP), and 
artesunate + amodiaquine (AS+AQ) is shown for all partici-
pants, and after excluding clinical treatment failures.Malaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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Grading severity of adverse events
In theory, severity grading should be the most objective
parameter of adverse event reporting. However, clinical
assessment and classification of severity may vary between
physicians and between sites, even when a grading scale is
applied. In addition, the severity categories for many
symptoms are driven by the decision to treat; events that
do not require treatment are classified as mild, while
events that require treatment, intervention, and/or moni-
toring are considered moderate. Treatment decisions may
also vary by site, and are likely to be different in Africa
than in developed countries. Classifying more serious
events as severe or life-threatening may also be subjective,
particularly for clinical variables, and merging these two
categories may help simplify severity grading.
Methods of data capture
In an attempt to focus on more clinically relevant events,
and to minimize the extra work associated with adverse
event reporting, in most studies physicians were required
to collect additional information, including suspected
relationship, only on events of moderate or greater sever-
ity. This system may have provided an incentive for the
study physicians to downgrade the severity classification.
Variation in the proportion of events graded as 'mild' at
the various sites (Table 2) would seem to support this, as
greater consistency in severity grading between sites
would be expected. Revising the system to capture data on
all events, regardless of severity, may improve reporting,
but will also generate even more data on potentially less
relevant events. Focusing assessment on patient-reported
events (rather than systematically screening for specific
symptoms and exam findings), or limiting evaluation to
serious adverse events and laboratory abnormalities, may
also limit the data burden, but may underestimate differ-
ences in tolerability.
Duration of follow-up
Standardized guidelines on the duration of follow-up for
safety monitoring are also needed. The duration of follow-
up for monitoring of adverse events after antimalarial
therapy is variable, often coinciding with the recom-
mended length of follow-up for efficacy outcomes of 28
or 42 days [5,6,13,15,24,25]. As for drug efficacy, the
duration of adverse event assessment should be deter-
mined by the elimination half-life of the drugs under eval-
uation; however, the timing of active assessments for drug
safety may be different than those for efficacy. In the lon-
gitudinal study in Kampala, few differences in the com-
parative risk of adverse events at 14 and 42 days of follow-
up were found. In that study, active surveillance for
adverse events was conducted until day 14, followed by
passive surveillance. Detailed assessments for safety and
tolerability conducted within the first two weeks of drug
treatment are likely to have the greatest yield. Depending
on the regimen, continued assessment for evidence of
serious adverse events and laboratory toxicity may extend
beyond that time.
Determining causal associations between adverse events 
and treatment
Determining if an adverse event is causally related to treat-
ment is a critical step in drug safety monitoring. However,
establishing causal associations is challenging, and classi-
fication of relationship can be subjective and insensitive.
In these studies, despite using a standard protocol and
similar approaches to training, assessment of relationship
lacked consistency. The majority of events (95%) were
classified as unlikely or possibly related to the study med-
ications; classification of an event as 'probably' related to
the study treatment occurred rarely. This likely reflects the
difficulty in ruling out alternative etiologies for an event,
or an understandable reluctance on the part of physicians
to commit to more definite relationship classes. Assess-
ment for causality requires careful consideration of vari-
ous factors including the timing of the event, the timing of
the treatment, response to antimalarial therapy, presence
of concomitant illnesses, and administration of concomi-
tant medications and herbal therapies. Algorithms based
on a decision tree considering these factors could be
developed to help standardize assessment of the relation-
ship between adverse events and antimalarial treatment.
Analytical challenges: Limited sample size, pooling data, 
multiple comparisons
Antimalarial clinical trials are typically designed and pow-
ered to test hypotheses about efficacy. As a result, the sam-
ple size of trials generally limits the ability to detect
uncommon events. The safety data collected at the differ-
ent sites was to be pooled in order to increase the power
to detect differences between the study treatments. How-
ever, significant differences in baseline characteristics, and
patterns of drug use, were observed between the study
sites. In addition, despite using a standardized protocol
and similar training, differences in adverse event assess-
ment and reporting at the different sites were observed,
which complicated the analysis. The potential for such
variation in baseline characteristics and adverse event
monitoring may significantly impact on the ability to
effectively combine data collected in different studies and
sites, even if standardized protocols are used. Analysis of
safety data is also challenged by the impact of multiple
comparisons on hypothesis testing. The likelihood that
significant differences between treatments may be found
just by chance increases with the number of comparisons
made, which may need to be taken into account when
designing studies and interpreting results.Malaria Journal 2008, 7:107 http://www.malariajournal.com/content/7/1/107
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Clinical treatment failure is a confounder
In the studies of single episodes of malaria, clinical treat-
ment failure appeared to confound the association
between study treatment and certain adverse events, par-
ticularly in areas of lower transmission intensity. A study
participant who fails initial therapy and develops early
treatment failure or recurrent clinical malaria will present
with the signs and symptoms of acute illness, which will
be captured as adverse events. In areas of high transmis-
sion, where participants are at risk of developing new
infections within the study follow-up period, this will be
an issue even if the drugs are highly efficacious. Thus, the
efficacy of an antimalarial regimen for treating the initial
infection, and for preventing new infections, will be asso-
ciated with the risk of adverse events. One approach,
which was considered, is to restrict the analysis by exclud-
ing treatment failures. However, excluding treatment fail-
ures limits the available data, particularly in areas of high
transmission. Controlling for treatment failure and other
relevant factors in a multivariate analysis is another
approach. Alternatively, this problem could be addressed
in the study design. In the longitudinal study of repeated
malaria treatment episodes, a new cycle of adverse event
reporting began with each new episode of malaria, and
symptoms noted on that day were not considered adverse
events but rather baseline for the new episode. However,
the cohort study design may not be optimal for all set-
tings.
Conclusion
Further studies are needed to establish the safety profiles
of newer antimalarial regimens in Africa, particularly with
widespread use. Despite prospectively evaluating for
adverse events using standardized methods modelled on
currently available international guidelines, limitations in
the system were identified. New guidelines for monitoring
for safety and tolerability in antimalarial trials are needed.
Although the WHO has acknowledged the need for phar-
macovigilance, and has taken the lead in supporting the
development pharmacovigilance systems in African coun-
tries deploying ACTs, additional guidance on adverse
events monitoring in antimalarial clinical trials would be
welcomed [2,26]. Such guidelines could include recom-
mendations on methods of data collection, including lab-
oratory testing, defining and identifying adverse events,
grading severity, classifying relationship, and analyzing
and reporting the data. Severity grading criteria could be
standardized and revised to be more relevant to local set-
tings, and algorithms for classifying relationship could be
developed. Standardized guidelines for gathering safety
data in antimalarial trials should specifically address how
to detect events of greatest importance (including severe
and life-threatening events, those with a causal relation-
ship to the treatment, those which impact on adherence,
and events not previously reported) while limiting the
amount of data collected.
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